Lastly, although high MSH2 expression correlates with poor patient prognosis, we cannot exclude the possibility that MSH2 acts as a surrogate marker for glioma grade rather than an independent prognostic driver, which will require future clinical and multivariate analyses for clarification. The gene discussed is MSH2; the disease is central nervous system cancer.